NECLIFE11.90

Nectar Lifesciences Limited

· Pharma & Health
₹ CrorePeersAAREYDRUGSNATCAPSUQMEDICAMEQMEDICOBALPHARMAALPAKREBSBIOHALEOSLABSMcap ₹231 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt635.5582.00.00.0
Net Debt615.2562.3-13.0-13.0
Total Debt/Equity0.590.610.000.00
Net Debt/Equity0.580.59-0.02-0.02
Total Debt/EBITDA4.15-22.000.000.00
Net Debt/EBITDA4.02-21.250.210.15
Interest Coverage (EBIT/Interest)1.06-1.19-1.69-1.69
Total Debt/Total Capital %37.2837.840.000.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.